This comes up a lot and I want to gently push back on something I see repeated as reassurance: “my pharmacy sends a certificate of analysis so I know it’s safe.” A CoA for a compounded injectable typically shows potency and purity results from HPLC testing. That tells you the active compound is present at roughly the stated concentration, and that certain known impurities aren’t above threshold. That is genuinely useful information. What it does not tell you is whether the vial is sterile. Sterility testing (USP <71>) and bacterial endotoxin testing (USP <85>) are separate analytical methods entirely. Endotoxins are breakdown products from gram-negative bacteria. You can kill the bacteria and the endotoxins stay behind, and they are what cause the fever and inflammatory response people sometimes attribute to “a bad batch” or “injection site reaction.” HPLC won’t find them. The ProRx situation is worth understanding in that light. The FDA findings that led to their shutdown were about sterility failures in the production environment, not about the tirzepatide molecule itself being wrong. Their purity numbers may well have looked fine on paper. That’s the gap. I’m not saying every compounding pharmacy is cutting corners. Some do run full sterility and endotoxin panels and will share them if you ask specifically. But “we test our products” and “we test for sterility and endotoxins on each lot” are two different statements. If you’re using a compounded injectable and want to actually assess the safety picture, that’s the specific question worth asking your pharmacy.
That ProRx situation is important, but I’d push back: from what I’ve looked into, most established compounders do list sterility and endotoxin testing upfront - you don’t typically have to hunt for it. Any pharmacy getting cagey about the data is already showing red flags. So yes, ask the question - but most won’t hesitate to answer.
“most established compounders do list sterility and endotoxin testing upfront” - that’s true for marketing copy, and I’d agree the cagey-pharmacy flag is real. but listing it and providing the actual lot-specific CoC (certificate of conformance) or endotoxin test report for the vial you’re injecting are different things. a pharmacy can have sterility testing as part of their general QC program and still release lots before results are back, which is a known compliance gap the FDA has cited in 483s. the ProRx findings weren’t about a pharmacy that hid their testing program - they had one. the failures were environmental controls and process. so “they test” being visible upfront doesn’t close the loop on whether your specific lot passed. lot number + specific panel results is the ask, not just confirmation that the program exists.
The lot-specific endotoxin and sterility results are what you’re actually asking for, not just confirmation the program exists - that’s the gap between policy and proof. I’m on tirzepatide myself but from a prescribed source, not compounded, so I haven’t worked through this directly. When you ask a pharmacy for those specific panels by lot number, do most provide them readily, or is that where the caginess actually starts?
USP <71> sterility results still leave a floor worth naming: the test is destructive, meaning it’s run on a sample of the lot, not every vial you receive. “We test for sterility on each lot” and “your specific vial is sterile” are still two different statements. Same logical gap the OP describes, just one level deeper than where the post ends. Better docs are better, but they don’t fully close it.
the 14-day incubation window for USP <71> is the part most people don’t realize: by the time that sterility result actually exists, the lot is already distributed and potentially injected. some pharmacies use rapid alternative methods (pharmacopeial chapter <1071> covers some of them) but those require validation and aren’t universal. the endotoxin piece is maybe more actionable to ask about directly bc BET (the LAL assay) turns around in hours, not weeks, so a pharmacy that’s doing it should be able to show you a lot-specific result without much lag. what i’ve found when actually calling pharmacies and asking: most will tell you they “perform testing,” a smaller number can immediately name the specific panels and reference USP <85> by number, and a very small subset will email you the actual endotoxin report for your lot within a day. that last group is the meaningful signal. the ProRx situation is a good anchor point here bc the FDA 483 observations were about environmental monitoring and production controls, which are upstream of any final product test anyway. a clean CoA on a product made in a compromised environment is exactly the scenario that makes the purity number misleading.